Adial Pharmaceuticals (ADIL) EBT (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted EBT of -$2.0 million for Q1 2026, up 66.34% sequentially from -$5.8 million in Q3 2025, and up 16.14% YoY from -$1.7 million in Q1 2025.
Adial Pharmaceuticals (ADIL) EBT (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported EBT for 10 years, with the latest figure at -$2.0 million in Q1 2026.
- Quarterly EBT rose 16.14% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (up 25.73% YoY) and the FY2025 annual result came in at -$24.4 million, down 84.86% from the prior year.
- EBT improved to -$2.0 million in Q1 2026 per ADIL's latest filing, from -$5.8 million in the prior quarter.
- Over five years, EBT peaked at -$1.3 million in Q3 2023 and troughed at -$11.1 million in Q3 2024.
- A 5-year average of -$3.3 million and a median of -$2.5 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT plunged 725.6% in 2024, then jumped 64.01% in 2025.
- Over 5 years, EBT stood at -$2.5 million in 2022, then rose by 25.31% to -$1.9 million in 2023, then gained by 24.21% to -$1.4 million in 2024, then tumbled by 302.35% to -$5.8 million in 2025, then surged by 66.34% to -$2.0 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$2.0 million, -$5.8 million, and -$2.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 81.49 Mn |
| 10 | Adial Pharmaceuticals | 27.37 Mn | 27.37 Mn | - | -51.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.95 Mn |
| Sep 30, 2025 | -5.81 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Mar 31, 2025 | -2.33 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | -11.13 Mn |
| Jun 30, 2024 | -2.46 Mn |
| Mar 31, 2024 | -6.48 Mn |
| Dec 31, 2023 | -1.90 Mn |
| Sep 30, 2023 | -1.35 Mn |
| Jun 30, 2023 | -1.51 Mn |
| Mar 31, 2023 | -2.24 Mn |
| Dec 31, 2022 | -2.55 Mn |
| Sep 30, 2022 | -2.55 Mn |
| Jun 30, 2022 | -3.24 Mn |
| Mar 31, 2022 | -2.91 Mn |
| Dec 31, 2021 | -5.92 Mn |
| Sep 30, 2021 | -4.32 Mn |
| Jun 30, 2021 | -4.44 Mn |
| Mar 31, 2021 | -4.83 Mn |